SCHEMBL30979532

SCHEMBL30979532

O=C(O)Cc1ncc(O)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGBL2 Q5U5Z8 2/20 0.53
GABRR1 P24046 2/20 0.37
KDM4E B2RXH2 3/20 0.36
MAPT P10636 3/20 0.36
POLB P06746 2/20 0.36
TSHR P16473 2/20 0.36
NFKB1 P19838 2/20 0.36
HSD17B10 Q99714 2/20 0.36
PMP22 Q01453 2/20 0.36
RGS12 O14924 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
APEX1 P27695 1/20 0.36
THPO P40225 1/20 0.36
BLM P54132 1/20 0.36
GNAI1 P63096 1/20 0.36
HIF1A Q16665 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27462826 1.00 AGBL2 (0.53) AGBL2GABRR1KDM4EMAPTPOLB
SCHEMBL29781576 0.83 AGBL2 (0.69) AGBL2GABRR1KDM4ELMNAASPH
SCHEMBL4530478 0.83 AGBL2 (0.69) AGBL2GABRR1KDM4ELMNAASPH
SCHEMBL17653807 0.80 AGBL2 (0.60) AGBL2GABRR1KDM4EMAPTPOLB
SCHEMBL1256353 0.80 AGBL2 (0.51) AGBL2GABRR1KDM4EPOLBTSHR
SCHEMBL30349490 0.80 AGBL2 (0.51) AGBL2GABRR1LMNAAKR1B1
SCHEMBL4528011 0.80 AGBL2 (0.51) AGBL2GABRR1LMNAAKR1B1
SCHEMBL30745351 0.80 HSP90AB1 (0.46) AGBL2KDM4EMAPTLMNAGAA
SCHEMBL14677488 0.80 HSP90AB1 (0.46) AGBL2KDM4EMAPTLMNAGAA
SCHEMBL24791807 0.77 P4HTM (0.50) P4HTMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624018-B1 Inhibitors of RIPK2 and medical uses thereof ODYSSEY THERAPEUTICS, INC. (US) 2026-05-12 US disclosed
EP-4622970-A1 INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2025-10-01 EP disclosed
WO-2024112854-A1 INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2024-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624018-B1 Inhibitors of RIPK2 and medical uses thereof RIPK2, RIPK1, RIPK4 AGBL2 1299/4885GABRR1 4472/4885KDM4E 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.